Twist Bioscience Corporation (TWST) Q3 2020 Earnings Results

Twist Bioscience Misses on EPS, Stock Down 1.13%

Twist Bioscience's earnings report showed a loss that was slightly better than expected, but the lack of revenue details and guidance may have contributed to the stock's decline of 1.13%. Investors may be concerned about the company's growth trajectory without clear future expectations. The cautious tone from management suggests they are aware of market challenges ahead.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.67	N/A	+6.29%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious optimism about the company's future. They acknowledged current market challenges while emphasizing their commitment to innovation.

Management highlighted ongoing efforts to expand product offerings.

They noted challenges in the market but expressed confidence in long-term growth.

Twist Bioscience Misses on EPS, Stock Down 1.13%

Key numbers

Management commentary

Twist Bioscience Corporation

More earnings this week

Twist Bioscience Misses on EPS, Stock Down 1.13%

Key numbers

Management commentary